Elliott J, Baines S
Willows Veterinary Centre & Referral Service, Highlands Road, Solihull, B90 4NH, United Kingdom.
Aust Vet J. 2019 Sep;97(9):308-315. doi: 10.1111/avj.12847. Epub 2019 Jul 22.
Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL). All patients responded to either CEOP or LEOP. Toxicity was typical of multi-agent chemotherapy protocols and 25% of dogs receiving lomustine exhibited mild-to-moderate ALT elevation and 29% grade 3 or 4 neutropenia. Median progression-free survival (100 versus 269 days) and overall survival (155 versus 327 days) were significantly higher in patients receiving LEOP compared to CEOP. Overall survival was improved for patients receiving LEOP compared to those receiving CEOP followed by lomustine-based rescue therapy. The results of this retrospective study support further evaluation of lomustine as part of first-line, multi-agent therapy for patients with HGTCL.
多药联合化疗（长春新碱、表柔比星和泼尼松龙），联合环磷酰胺（CEOP）或洛莫司汀（LEOP），作为一线化疗方案用于初治的、可测量的高分级T细胞淋巴瘤（HGTCL）犬淋巴瘤患者。所有患者对CEOP或LEOP均有反应。毒性反应是多药联合化疗方案的典型表现，接受洛莫司汀治疗的犬中有25%出现轻度至中度谷丙转氨酶升高，29%出现3级或4级中性粒细胞减少。与接受CEOP治疗的患者相比，接受LEOP治疗的患者的中位无进展生存期（分别为100天和269天）和总生存期（分别为155天和327天）显著更长。与接受CEOP治疗后再接受基于洛莫司汀的挽救治疗的患者相比，接受LEOP治疗的患者的总生存期有所改善。这项回顾性研究的结果支持进一步评估洛莫司汀作为HGTCL患者一线多药联合治疗的一部分。
